A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Recruiting

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

Trial locations(2 sites)

China

Beijing Cancer hospital, Beijing, Beijing Municipality

The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi